Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$224.03 -3.25 (-1.43%)
At close: Oct 23, 2026 · 4:00 PM EDT

Alnylam Pharmaceuticals (ALNY) Return on Sales [ROS] (2009 - 2026)

Updated

Alnylam Pharmaceuticals' Return on Sales [ROS] came in at 17.93% for Q2 2026, up 20.02 percentage points from -2.09% a year earlier but down 5.09 percentage points from the prior quarter.

Analysis

Alnylam Pharmaceuticals (ALNY) Return on Sales [ROS] (2009 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Alnylam Pharmaceuticals reported Return on Sales [ROS] of 20.81%, up 30.31 percentage points year-over-year; for FY2025, it came in at 13.51%, up 21.37 percentage points from FY2024.

  • Return on Sales [ROS] has increased in each of the last seven years, with a five-year change of +181.60 percentage points (FY2020 to FY2025).
  • Going back by year, Return on Sales [ROS] was -7.87% in FY2024 (+7.57 pp), -15.43% in FY2023 (+60.24 pp), -75.68% in FY2022 (+8.26 pp) and -83.93% in FY2021 (+84.16 pp).
  • The five-year range for quarterly Return on Sales [ROS] is -97.63% (Q3 2022) to 60.26% (Q1 2025).
  • Year-over-year, Return on Sales [ROS] increased in five of the last eight quarters, with an average year-over-year change of +10.23 percentage points.
  • The fastest year-over-year change in Return on Sales [ROS] over five years came in Q3 2023 (a gain of 126.12 percentage points), and the weakest in Q3 2024 (a drop of 43.85 percentage points).
  • Business Quant data shows ALNY's Return on Sales [ROS] at 23.02% (Q1 2026), 12.01% (Q4 2025) and 29.46% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 24.35%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 37.86%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 20.57%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -133.21%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 28.37%
10 Alnylam Pharmaceuticals 29.96 Bn 18.01 Bn 992.69 Mn 17.93%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17.93%
Mar 31, 2026 23.02%
Dec 31, 2025 12.01%
Sep 30, 2025 29.46%
Jun 30, 2025 -2.09%
Dec 31, 2024 -17.73%
Sep 30, 2024 -15.35%
Jun 30, 2024 7.37%
Mar 31, 2024 -8.79%
Dec 31, 2023 -26.47%
Sep 30, 2023 28.50%
Jun 30, 2023 -72.10%
Mar 31, 2023 -46.92%
Dec 31, 2022 -56.30%
Sep 30, 2022 -97.63%
Jun 30, 2022 -85.26%
Mar 31, 2022 -68.80%
Dec 31, 2021 -75.26%
Sep 30, 2021 -96.83%
Jun 30, 2021 -66.27%
API Access

Alnylam Pharmaceuticals Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ALNY&period=max&api_key=YOUR_API_KEY